00:00Moderna and Merck say their personalized mRNA cancer vaccine significantly reduced the risk of melanoma returning or spreading when paired
00:09with Merck's Keytruda.
00:10The phase 3 trial involved more than 1,100 patients with high-risk melanoma and marks the first successful late
00:18-stage trial for an mRNA cancer vaccine.
00:21The treatment is customized to target mutations unique to each patient's tumor, potentially opening a new chapter for personalized cancer
00:29care.
00:29Moderna's shares surged following the announcement, while the companies prepare to present more detailed results and pursue regulatory approval.
Comments